Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia/reperfusion injury by limiting tumour necrosis factor alpha–induced mitochondrial injury in experimental diabetes
Cardiovascular Research · 14.10.2024 · 120 (12) · 1456-1471
DOI: 10.1093/cvr/cvae144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 13.07.2024. Verfasst von Shelley L Baumgardt und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53206, USA. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Mitochondria, Heart, Diabetes Mellitus, Experimental, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Surgery at Ann & Robert H. Lurie Children's Hospital of Chicago, USA, NHLBI NIH HHS, NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The histone deacetylase 6 (HDAC6) inhibitor, tubastatin A (TubA), reduces myocardial ischaemia/reperfusion injury (MIRI) in type 1 diabetic rats. It remains unclear whether HDAC6 regulates MIRI in type 2 diabetic animals. Diabetes augments the activity of HDAC6 and the generation of tumour necrosis factor alpha (TNF-α) and impairs mitochondrial complex I (mCI). Here, we examined how HDAC6 regulates TNF-α production, mCI activity, mitochondria, and cardiac function in type 1 and type 2 diabetic mice undergoing MIRI. Methods and results HDAC6 knockout, streptozotocin-induced type 1 diabetic, and obese type 2 diabetic db/db mice underwent MIRI in vivo or ex vivo in a Langendorff-perfused system. We found that MIRI and diabetes additively augmented myocardial HDAC6 activity and generation of TNF-α, along with cardiac mitochondrial fission, low bioactivity of mCI, and low production of adenosine triphosphate. Importantly, genetic disruption of HDAC6 or TubA decreased TNF-α levels, mitochondrial fission, and myocardial mitochondrial nicotinamide adenine dinucleotide levels in ischaemic/reperfused diabetic mice, concomitant with augmented mCI activity, decreased infarct size, and improved cardiac function. Moreover, HDAC6 knockout or TubA treatment decreased left ventricular dilation and improved cardiac systolic function 28 days after MIRI. H9c2 cardiomyocytes with and without HDAC6 knockdown were subjected to hypoxia/reoxygenation injury in the presence of high glucose. Hypoxia/reoxygenation augmented HDAC6 activity and TNF-α levels and decreased mCI activity. These negative effects were blocked by HDAC6 knockdown.
Conclusion
HDAC6 is an essential negative regulator of MIRI in diabetes. Genetic deletion or pharmacologic inhibition of HDAC6 protects the heart from MIRI by limiting TNF-α–induced mitochondrial injury in experimental diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53206, USA.
- Department of Pediatrics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53206, USA.
- Cardiovascular-Thoracic Surgery and the Heart Center, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, 303 E. Super…
- Department of Pediatrics, Feinberg School of Medicine, Northwestern University, 225 E. Chicago Avenue, Chicago, IL 60611, USA.
- Department of Surgery, Feinberg School of Medicine, Northwestern University, 225 E. Chicago Avenue, Chicago, IL 60611, USA.
- Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, The People's Republic of China.
ORCID-Profile: Zhengyuan Xia, Zhi-Dong Ge
Förderung
- Department of Surgery at Ann & Robert H. Lurie Children's Hospital of Chicago, USA
- NHLBI NIH HHS
- NIH HHS
- NIGMS NIH HHS
- National Science Foundation
- National Institutes of Health
- Department of Surgery at Ann & Robert H. Lurie Children’s Hospital of Chicago, USA
Zitieren
APA
Baumgardt, S. L., Fang, J., Fu, X., Liu, Y., Xia, Z., Zhao, M., Chen, L., Mishra, R., Gunasekaran, M., Saha, P., Forbess, J. M., Bosnjak, Z. J., Camara, A. K. S., Kersten, J. R., Thorp, E. B., Kaushal, S., & Ge, Z. D. (2024). Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia/reperfusion injury by limiting tumour necrosis factor alpha–induced mitochondrial injury in experimental diabetes. Cardiovascular Research, 120(12), 1456-1471. https://doi.org/10.1093/cvr/cvae144
Vancouver
Baumgardt SL, Fang J, Fu X, Liu Y, Xia Z, Zhao M, et al. Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia/reperfusion injury by limiting tumour necrosis factor alpha–induced mitochondrial injury in experimental diabetes. Cardiovascular Research. 2024;120(12):1456-1471. doi:10.1093/cvr/cvae144
BibTeX
@article{Baumgardt2024,
author = {Baumgardt, Shelley L and Fang, Juan and Fu, Xuebin and Liu, Yanan and Xia, Zhengyuan and Zhao, Ming and Chen, Ling and Mishra, Rachana and Gunasekaran, Muthukumar and Saha, Progyaparamita and Forbess, Joseph M and Bosnjak, Zeljko J and Camara, Amadou K S and Kersten, Judy R and Thorp, Edward B and Kaushal, Sunjay and Ge, Zhi-Dong},
title = {Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia/reperfusion injury by limiting tumour necrosis factor alpha–induced mitochondrial injury in experimental diabetes},
journal = {Cardiovascular Research},
year = {2024},
volume = {120},
number = {12},
pages = {1456--1471},
doi = {10.1093/cvr/cvae144}
}
EUVIMED